VX-765 (Epilepsy)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Classification of Seizures 14
3.2 Etiology and Pathophysiology 15
3.2.1 Etiology 15
3.2.2 Pathophysiology 18
3.2.3 Prognosis 23
3.2.4 Quality of Life 24
4 Disease Management 25
4.1 Diagnosis 25
4.2 Treatment Guidelines 26
4.3 Clinical Practice 27
5 Competitive Assessment 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 35
6 Opportunity and Unmet Need 38
6.1 Overview 38
6.2 Unmet Needs 39
6.2.1 Refractory Epilepsy 39
6.2.2 Safety/Side Effect Profiles 39
6.2.3 Curative/Disease-Modifying Agents 40
6.2.4 Predictive Tools and Need for More Directed Treatments 41
6.2.5 Improved Preclinical Models and Clinical Trial Paradigms 41
6.2.6 Treatment Gap 42
6.3 Unmet Needs Gap Analysis 43
6.4 Opportunities 44
6.4.1 Disease-Modifying Agents 44
6.4.2 Improved Preclinical Models and Clinical Trial Paradigms 44
6.4.3 Treatment Gap 44
7 Pipeline Assessment 45
7.1 Overview 45
7.2 Strategic Pipeline Assessment 45
7.3 Pipeline by Phases of Development 46
7.3.1 Phase III Pipeline 46
7.3.2 Phase III Pipeline – Reformulations/New Delivery Systems 47
7.3.3 Phase IIb Pipeline 47
7.3.4 Phase II Pipeline 48
7.3.5 Phase I Pipeline 48
7.3.6 Preclinical Pipeline 49
7.3.7 Discovery Pipeline 50
7.4 Pipeline by Mechanism of Action 50
7.5 Promising Drugs in Clinical Development 52
8 VX-765 53
8.1 Overview 53
8.2 Efficacy 54
8.3 Safety 54
8.4 Dosing and Formulation 55
8.5 Potential Clinical Positioning 55
8.6 Potential Commercial Positioning 55
8.7 Pricing and Reimbursement 55
8.8 SWOT Analysis 55
8.9 Forecast 56
9 Appendix 57
9.1 Bibliography 57
9.2 Abbreviations 59
9.3 Methodology 61
9.4 Forecasting Methodology 61
9.4.1 Prevalent Epilepsy Patients 61
9.4.2 Percent Drug-Treated Patients 62
9.4.3 General Pricing Assumptions 62
9.4.4 Generic Erosion 63
9.4.5 Pricing of Pipeline Agents 63
9.5 Physicians and Specialists Included in this Study 63
9.6 Primary Research – Prescriber Survey 64
9.7 About the Authors 65
9.7.1 Authors 65
9.7.2 Global Head of Healthcare 66
9.8 About GlobalData 67
9.9 Contact Us 67
9.10 Disclaimer 67